Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Licenses Dx Rights to Moffitt Proteins for Lung Cancer Test

NEW YORK (GenomeWeb News) – Genzyme has licensed the diagnostic testing rights to two proteins from the Moffitt Cancer Center that it plans to develop into tests that could help predict patients’ response to non-small cell lung cancer treatments, the company said today.
Tampa, Fla.-based Moffitt, designated a Comprehensive Cancer Center by the National Cancer Institute, has found that the proteins RRM1 and ERCC1 may help to predict the effectiveness of NSCLC treatments, because the expression levels of the proteins correlated to responses to two common drugs.
Genzyme said it will develop and market a diagnostic test to measure the expression level of these proteins in NSCLC patients in order to help direct doctors trying to make first-line treatment decisions. Cambridge, Mass.-based Genzyme will provide Moffitt with milestone payments and royalties from the sale of any licensed products or services stemming from the research.
Genzyme’s national medical director, Bruce Horten, said the first-line treatment step for NSCLC is “a key decision point in the management of patients for whom getting the right drug as quickly as possible is critical.”

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.